DAX24.168 +0,5%ESt505.432 +1,0%Top 10 Crypto14,54 +0,3%Dow42.099 -0,6%Nas19.101 -0,5%Bitcoin95.760 -0,2%Euro1,1277 -0,2%Öl65,89 +1,4%Gold3.279 -0,3%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
NVIDIA 918422 Rheinmetall 703000 RENK RENK73 HENSOLDT HAG000 Tesla A1CX3T BYD A0M4W9 Siemens Energy ENER6Y Lufthansa 823212 D-Wave Quantum A3DSV9 thyssenkrupp 750000 Mercedes-Benz Group (ex Daimler) 710000 BASF BASF11 Deutsche Bank 514000 Daimler Truck DTR0CK Bayer BAY001
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
DAX positiv - Rekord im Blick -- Asiens Börsen freundlich -- NVIDIA übertrifft Erwartungen -- US-Gericht erklärt Trumps Zölle für rechtswidrig -- GSK, Bilfinger, Deutsche Telekom, IONOS im Fokus
Top News
Marktausblick: DAX nimmt Allzeithoch ins Visier - NVIDIA & Trump-Zoll-Schlappe treiben Marktausblick: DAX nimmt Allzeithoch ins Visier - NVIDIA & Trump-Zoll-Schlappe treiben
Für den Marktabschwung positioniert: So hat der Big Short-Investor Michael Burry im ersten Quartal 2025 investiert Für den Marktabschwung positioniert: So hat der Big Short-Investor Michael Burry im ersten Quartal 2025 investiert
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Immunic Aktie

Handeln
Immunic Aktien-Sparplan
0,6920 EUR -0,0850 EUR -10,94 %
FSE
0,7624 USD -0,1605 USD -17,39 %
nachbörslich
BTT
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.77,36 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PHD4

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS4525EP1011

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolIMUX

Immunic Aktien News

DatumMeistgelesen
EQS GroupEQS-News: Immunic to Participate in Scientific and Industry Conferences in May
PR NewswireImmunic to Participate in Scientific and Industry Conferences in May
EQS GroupEQS-News: Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
Wer­bungImmunic-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireImmunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
EQS GroupEQS-News: Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS GroupEQS-News: Immunic, Inc. Announces Pricing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
EQS GroupEQS-News: Immunic, Inc. to Participate in Scientific and Industry Conferences in April
PR NewswireImmunic, Inc. to Participate in Scientific and Industry Conferences in April
EQS GroupEQS-News: Immunic to Participate in Scientific and Investor Conferences in March
PR NewswireImmunic to Participate in Scientific and Investor Conferences in March
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
PR NewswireImmunic's Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
EQS GroupEQS-News: Immunic to Participate in Investor and Scientific Conferences in February
PR NewswireImmunic to Participate in Investor and Scientific Conferences in February
EQS GroupEQS-News: Immunic Highlights 2024 Accomplishments and Upcoming Milestones
PR NewswireImmunic Highlights 2024 Accomplishments and Upcoming Milestones
EQS GroupEQS-News: Immunic, Inc. to Participate in Investor Conference in December
PR NewswireImmunic, Inc. to Participate in Investor Conference in December
EQS GroupEQS-News: Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
PR NewswireImmunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology
EQS GroupEQS-News: Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
EQS GroupEQS-News: Immunic to Participate in Industry, Scientific and Investor Conferences in November
PR NewswireImmunic to Participate in Industry, Scientific and Investor Conferences in November
EQS GroupEQS-News: Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
PR NewswireImmunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple Sclerosis
EQS GroupEQS-News: Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
PR NewswireImmunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple Sclerosis
EQS GroupEQS-News: Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
PR NewswireImmunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID Syndrome
EQS GroupEQS-News: Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
PR NewswireImmunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in September
EQS GroupEQS-News: Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
PR NewswireImmunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate Update
EQS GroupEQS-News: Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
PR NewswireImmunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
Wer­bung

Immunic News

Immunic News: auf dieser Seite finden Sie alle Immunic News und Nachrichten zur Immunic Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Immunic News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Immunic News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.